12 results on '"Carter, Cristina"'
Search Results
2. Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial
- Author
-
Houser, Katherine V., Chen, Grace L., Carter, Cristina, Crank, Michelle C., Nguyen, Thuy A., Burgos Florez, Maria Claudia, Berkowitz, Nina M., Mendoza, Floreliz, Hendel, Cynthia Starr, Gordon, Ingelise J., Coates, Emily E., Vazquez, Sandra, Stein, Judy, Case, Christopher L., Lawlor, Heather, Carlton, Kevin, Gaudinski, Martin R., Strom, Larisa, Hofstetter, Amelia R., Liang, C. Jason, Narpala, Sandeep, Hatcher, Christian, Gillespie, Rebecca A., Creanga, Adrian, Kanekiyo, Masaru, Raab, Julie E., Andrews, Sarah F., Zhang, Yi, Yang, Eun Sung, Wang, Lingshu, Leung, Kwanyee, Kong, Wing-Pui, Freyn, Alec W., Nachbagauer, Raffael, Palese, Peter, Bailer, Robert T., McDermott, Adrian B., Koup, Richard A., Gall, Jason G., Arnold, Frank, Mascola, John R., Graham, Barney S., and Ledgerwood, Julie E.
- Published
- 2022
- Full Text
- View/download PDF
3. Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial
- Author
-
Arthur, Anita, Cunningham, Jennifer, Eshun, Aba, Larkin, Brenda, Mendoza, Floreliz, Novik, Laura, Saunders, Jamie, Wang, Xiaolin, Whalen, William, Carter, Cristina, Hendel, Cynthia Starr, Plummer, Sarah, Ola, Abidemi, Widge, Alicia, Burgos Florez, Maria C, Le, Lam, Pittman, Iris, Rothwell, Ro Shauna S, Trofymenko, Olga, Vasilenko, Olga, Apte, Preeti, Hicks, Renunda, Cartagena, Cora Trelles, Williams, Pernell, Requilman, LaShawn, Tran, Colin, Bai, Shufeng, Carey, Elizabeth, Chamberlain, Amy L, Chang, Ya-chen, Chen, Mingzhong, Chen, Peifeng, Cooper, Jon, Fridley, Colleen, Ghosh, Mridul, Gollapudi, Deepika, Holland-Linn, Janel, Horwitz, Joe, Hussain, Althaf, Ivleva, Vera, Kaltovich, Florence, Leach, Kristin, Lee, Christopher, Liu, Amy, Liu, Xun, Manceva, Slobodanka, Menon, Amritha, Nagy, Attila, O'Connell, Sarah, Ragunathan, Rahul, Walters, Jennifer, Zhao, Zhong, Ruckwardt, Tracy J, Morabito, Kaitlyn M, Phung, Emily, Crank, Michelle C, Costner, Pamela J, Holman, LaSonji A, Chang, Lauren A, Hickman, Somia P, Berkowitz, Nina M, Gordon, Ingelise J, Yamshchikov, Galina V, Gaudinski, Martin R, Lin, Bob, Bailer, Robert, Chen, Man, Ortega-Villa, Ana M, Nguyen, Thuy, Kumar, Azad, Schwartz, Richard M, Kueltzo, Lisa A, Stein, Judith A, Carlton, Kevin, Gall, Jason G, Nason, Martha C, Mascola, John R, Chen, Grace, and Graham, Barney S
- Published
- 2021
- Full Text
- View/download PDF
4. Food Allergy in Restaurants Work Group Report
- Author
-
Carter, Cristina A., Pistiner, Michael, Wang, Julie, and Sharma, Hemant P.
- Published
- 2020
- Full Text
- View/download PDF
5. Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial
- Author
-
Mendoza, Floreliz, Novik, Laura, Zephir, Kathy, Whalen, William, Larkin, Brenda, Saunders, Jamie, Cunningham, Jennifer, Levinson, Carol, Wang, Xiaolin, Plummer, Sarah, Victorino, Milalynn, Ola, Abidemi, Boyd, Catina, Jayasinghe, Nilusha, Apte, Preeti, Cartagena, Cora Trelles, Hicks, Renunda, Williams, Pernell, Vasilenko, Olga, Yamshchikov, Galina, Florez, Maria Burgos, Pittman, Iris, Gama, Lucio, Casazza, Joseph, DeCederfelt, Hope, Cheng, KC, Stein, Judy, Gaudinski, Martin R, Houser, Katherine V, Doria-Rose, Nicole A, Chen, Grace L, Rothwell, Ro Shauna S, Berkowitz, Nina, Costner, Pamela, Holman, LaSonji A, Gordon, Ingelise J, Hendel, Cynthia S, Kaltovich, Florence, Conan-Cibotti, Michelle, Gomez Lorenzo, Margarita, Carter, Cristina, Sitar, Sandra, Carlton, Kevin, Gall, Jason, Laurencot, Carolyn, Lin, Bob C, Bailer, Robert T, McDermott, Adrian B, Ko, Sung-Youl, Pegu, Amarendra, Kwon, Young D, Kwong, Peter D, Namboodiri, Aryan M, Pandey, Janardan P, Schwartz, Richard, Arnold, Frank, Hu, Zonghui, Zhang, Lily, Huang, Yunda, Koup, Richard A, Capparelli, Edmund V, Graham, Barney S, Mascola, John R, and Ledgerwood, Julie E
- Published
- 2019
- Full Text
- View/download PDF
6. T helper type 1 cytokines and keratinocyte growth factor play a critical role in pseudoepitheliomatous hyperplasia initiation during cutaneous leishmaniasis
- Author
-
Akilov, Oleg E., Donovan, Michael J., Stepinac, Thomas, Carter, Cristina R., Whitcomb, James P., Hasan, Tayyaba, and McDowell, Mary Ann
- Published
- 2007
- Full Text
- View/download PDF
7. Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial.
- Author
-
Chen, Grace L., Coates, Emily E., Plummer, Sarah H., Carter, Cristina A., Berkowitz, Nina, Conan-Cibotti, Michelle, Cox, Josephine H., Beck, Allison, O'Callahan, Mark, Andrews, Charla, Gordon, Ingelise J., Larkin, Brenda, Lampley, Rebecca, Kaltovich, Florence, Gall, Jason, Carlton, Kevin, Mendy, Jason, Haney, Doug, May, Jeanine, and Bray, Amy
- Subjects
VIRAL vaccines ,CHIKUNGUNYA ,IMMUNOGLOBULINS ,INTRAMUSCULAR injections ,RANDOMIZED controlled trials ,BLIND experiment ,NEUTRALIZATION tests ,STATISTICAL sampling ,CHIKUNGUNYA virus - Abstract
Importance: Chikungunya virus (CHIKV) is a mosquito-borne Alphavirus prevalent worldwide. There are currently no licensed vaccines or therapies.Objective: To evaluate the safety and tolerability of an investigational CHIKV virus-like particle (VLP) vaccine in endemic regions.Design, Setting, and Participants: This was a randomized, placebo-controlled, double-blind, phase 2 clinical trial to assess the vaccine VRC-CHKVLP059-00-VP (CHIKV VLP). The trial was conducted at 6 outpatient clinical research sites located in Haiti, Dominican Republic, Martinique, Guadeloupe, and Puerto Rico. A total of 400 healthy adults aged 18 through 60 years were enrolled after meeting eligibility criteria. The first study enrollment occurred on November 18, 2015; the final study visit, March 6, 2018.Interventions: Participants were randomized 1:1 to receive 2 intramuscular injections 28 days apart (20 µg, n = 201) or placebo (n = 199) and were followed up for 72 weeks.Main Outcomes and Measures: The primary outcome was the safety (laboratory parameters, adverse events, and CHIKV infection) and tolerability (local and systemic reactogenicity) of the vaccine, and the secondary outcome was immune response by neutralization assay 4 weeks after second vaccination.Results: Of the 400 randomized participants (mean age, 35 years; 199 [50%] women), 393 (98%) completed the primary safety analysis. All injections were well tolerated. Of the 16 serious adverse events unrelated to the study drugs, 4 (25%) occurred among 4 patients in the vaccine group and 12 (75%) occurred among 11 patients in the placebo group. Of the 16 mild to moderate unsolicited adverse events that were potentially related to the drug, 12 (75%) occurred among 8 patients in the vaccine group and 4 (25%) occurred among 3 patients in the placebo group. All potentially related adverse events resolved without clinical sequelae. At baseline, there was no significant difference between the effective concentration (EC50)-which is the dilution of sera that inhibits 50% infection in viral neutralization assay-geometric mean titers (GMTs) of neutralizing antibodies of the vaccine group (46; 95% CI, 34-63) and the placebo group (43; 95% CI, 32-57). Eight weeks following the first administration, the EC50 GMT in the vaccine group was 2005 (95% CI, 1680-2392) vs 43 (95% CI, 32-58; P < .001) in the placebo group. Durability of the immune response was demonstrated through 72 weeks after vaccination.Conclusions and Relevance: Among healthy adults in a chikungunya endemic population, a virus-like particle vaccine compared with placebo demonstrated safety and tolerability. Phase 3 trials are needed to assess clinical efficacy.Trial Registration: ClinicalTrials.gov Identifier: NCT02562482. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
8. Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial.
- Author
-
Carter, Cristina, Houser, Katherine V., Yamshchikov, Galina V., Bellamy, Abbie R., May, Jeanine, Enama, Mary E., Sarwar, Uzma, Larkin, Brenda, Bailer, Robert T., Koup, Richard, Chen, Grace L., Patel, Shital M., Winokur, Patricia, Belshe, Robert, Dekker, Cornelia L., Graham, Barney S., Ledgerwood, Julie E., and null, null
- Subjects
- *
DNA vaccines , *SEASONAL influenza , *VACCINES , *CLINICAL trials , *INFLUENZA vaccines - Abstract
Background: Seasonal influenza results in significant morbidity and mortality worldwide, but the currently licensed inactivated vaccines generally have low vaccine efficacies and could be improved. In this phase 1 clinical trial, we compared seasonal influenza vaccine regimens with different priming strategies, prime-boost intervals, and administration routes to determine the impact of these variables on the resulting antibody response. Methods: Between August 17, 2012 and January 25, 2013, four sites enrolled healthy adults 18–70 years of age. Subjects were randomized to receive one of the following vaccination regimens: trivalent hemagglutinin (HA) DNA prime followed by trivalent inactivated influenza vaccine (IIV3) boost with a 3.5 month interval (DNA-IIV3), IIV3 prime followed by IIV3 boost with a 10 month interval (IIV3-IIV3), or concurrent DNA and IIV3 prime followed by IIV3 boost with a 10 month interval (DNA/IIV3-IIV3). Each regimen was additionally stratified by an IIV3 administration route of either intramuscular (IM) or intradermal (ID). DNA vaccines were administered by a needle-free jet injector (Biojector). Study objectives included evaluating the safety and tolerability of each regimen and measuring the antibody response by hemagglutination inhibition (HAI). Results: Three hundred and sixteen subjects enrolled. Local reactogenicity was mild to moderate in severity, with higher frequencies recorded following DNA vaccine administered by Biojector compared to IIV3 by either route (p <0.02 for pain, swelling, and redness) and following IIV3 by ID route compared to IM route (p <0.001 for swelling and redness). Systemic reactogenicity was similar between regimens. Though no overall differences were observed between regimens, the highest titers post boost were observed in the DNA-IIV3 group by ID route and in the IIV3-IIV3 group by IM route. Conclusions: All vaccination regimens were found to be safe and tolerable. While there were no overall differences between regimens, the DNA-IIV3 group by ID route, and the IIV3-IIV3 group by IM route, showed higher responses compared to the other same-route regimens. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
9. Detection of Prostaglandin E2 and Matrix Metalloproteinases in Implant Crevicular Fluid.
- Author
-
Aboyoussef, Hoda, Carter, Cristina, Jandinski, John J., and Panagakos, Fotinos S.
- Subjects
CYTOKINES ,GINGIVAL hyperplasia ,METALLOPROTEINASES ,ACUTE phase proteins ,GINGIVAL fluid ,DENTAL implants - Abstract
Studies show that implants exhibiting peri-implantitis contain elevated levels of the cytokine interleukin-1β in the gingival crevicular fluid (GCF). This study further evaluated possible mechanisms of osseous loss in peri-implantitis by examining GCF samples for the presence of prostaglandin E
2 (PGE2 ) and proteolytic enzymes, specifically matrix metalloproteinases (MMPs). Results indicated that levels of PGE2 in healthy sites were not significantly different from those at diseased sites. MMP species migrated at 92 kd and 66 kd. No qualitative difference in bands was seen between healthy implants and those diagnosed with early peri-implantitis. Results suggested that PGE2 and MMP levels are not useful biologic markers for distinguishing between healthy and diseased implants. [ABSTRACT FROM AUTHOR]- Published
- 1998
10. A Native American Encyclopedia: History, Culture, and Peoples
- Author
-
Carter, Cristina E.
- Subjects
A Native American Encyclopedia: History, Culture, and Peoples (Book) ,Books -- Book reviews ,Business ,Library and information science - Abstract
A Native American Encyclopedia: History, Culture, and Peoples. By Barry M. Pritzker. New York: Oxford Univ. Pr., 2000. 607p. acid free $49.95 (ISBN 0-19-513897-X). www.oup.com. This volume was originally published [...]
- Published
- 2001
11. The Genetics of Food Allergy.
- Author
-
Carter, Cristina A. and Frischmeyer-Guerrerio, Pamela A.
- Abstract
Purpose of Review: Food allergy likely arises from a complex interplay between environmental triggers and genetic susceptibility. Here, we review recent studies that have investigated the genetic pathways and mechanisms that may contribute to the pathogenesis of food allergy.Recent Findings: A heritability component of food allergy has been observed in multiple studies. A number of monogenic diseases characterized by food allergy have elucidated pathways that may be important in pathogenesis. Several population-based genetic variants associated with food allergy have also been identified.Summary: The genetic mechanisms that play a role in the development of food allergy are heterogeneous and complex. Advances in our understanding of the genetics of food allergy, and how this predisposition interacts with environmental exposures to lead to disease, will improve our understanding of the key pathways leading to food allergy and inform more effective prevention and treatment strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
12. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study.
- Author
-
Gaudinski, Martin R., Coates, Emily E., Novik, Laura, Widge, Alicia, Houser, Katherine V., Burch, Eugeania, Holman, LaSonji A., Gordon, Ingelise J., Chen, Grace L., Carter, Cristina, Nason, Martha, Sitar, Sandra, Yamshchikov, Galina, Berkowitz, Nina, Andrews, Charla, Vazquez, Sandra, Laurencot, Carolyn, Misasi, John, Arnold, Frank, and Carlton, Kevin
- Subjects
- *
EBOLA virus disease prevention , *ANIMAL experimentation , *CLINICAL trials , *COMPARATIVE studies , *DOSE-effect relationship in pharmacology , *EBOLA virus disease , *IMMUNOLOGICAL adjuvants , *INTRAVENOUS therapy , *RESEARCH methodology , *MEDICAL cooperation , *MONOCLONAL antibodies , *PRIMATES , *PROTEINS , *RESEARCH , *RESEARCH funding , *VIRAL vaccines , *EVALUATION research , *EBOLA virus - Abstract
Background: mAb114 is a single monoclonal antibody that targets the receptor-binding domain of Ebola virus glycoprotein, which prevents mortality in rhesus macaques treated after lethal challenge with Zaire ebolavirus. Here we present expedited data from VRC 608, a phase 1 study to evaluate mAb114 safety, tolerability, pharmacokinetics, and immunogenicity.Methods: In this phase 1, dose-escalation study (VRC 608), conducted at the US National Institutes of Health (NIH) Clinical Center (Bethesda, MD, USA), healthy adults aged 18-60 years were sequentially enrolled into three mAb114 dose groups of 5 mg/kg, 25 mg/kg, and 50 mg/kg. The drug was given to participants intravenously over 30 min, and participants were followed for 24 weeks. Participants were only enrolled into increased dosing groups after interim safety assessments. Our primary endpoints were safety and tolerability, with pharmacokinetic and anti-drug antibody assessments as secondary endpoints. We assessed safety and tolerability in all participants who received study drug by monitoring clinical laboratory data and self-report and direct clinician assessment of prespecified infusion-site symptoms 3 days after infusion and systemic symptoms 7 days after infusion. Unsolicited adverse events were recorded for 28 days. Pharmacokinetic and anti-drug antibody assessments were completed in participants with at least 56 days of data. This trial is registered with ClinicalTrials.gov, number NCT03478891, and is active but no longer recruiting.Findings: Between May 16, and Sept 27, 2018, 19 eligible individuals were enrolled. One (5%) participant was not infused because intravenous access was not adequate. Of 18 (95%) remaining participants, three (17%) were assigned to the 5 mg/kg group, five (28%) to the 25 mg/kg group, and ten (55%) to the 50 mg/kg group, each of whom received a single infusion of mAb114 at their assigned dose. All infusions were well tolerated and completed over 30-37 min with no infusion reactions or rate adjustments. All participants who received the study drug completed the safety assessment of local and systemic reactogenicity. No participants reported infusion-site symptoms. Systemic symptoms were all mild and present only in four (22%) of 18 participants across all dosing groups. No unsolicited adverse events occurred related to mAb114 and one serious adverse event occurred that was unrelated to mAb114. mAb114 has linear pharmacokinetics and a half-life of 24·2 days (standard error of measurement 0·2) with no evidence of anti-drug antibody development.Interpretation: mAb114 was well tolerated, showed linear pharmacokinetics, and was easily and rapidly infused, making it an attractive and deployable option for treatment in outbreak settings.Funding: Vaccine Research Center, US National Institute of Allergy and Infectious Diseases, and NIH. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.